SIMCERE PHARMA (02096) invested HKD 10.7033 million to repurchase 929,000 shares, demonstrating the company's confidence in its long-term development.

SIMCERE PHARMA (02096) announced on the Hong Kong Stock Exchange that on September 9, it repurchased 929,000 shares at a price ranging from HKD 11.480 to HKD 11.554 per share, with a total repurchase amount of HKD 10.7033 million. The company has the authority to repurchase up to 256,819,861 shares by June 12, 2026, allowing for ample future repurchase capacity. This repurchase action demonstrates the management's strong confidence in the company's intrinsic value and long-term development. Recently, UBS has listed SIMCERE PHARMA as a top pick in the industry, noting that SIMCERE PHARMA is the only company to raise its guidance for 2026, with the adjusted net profit growth target increased from 30% to 45%, while maintaining a revenue growth target of 30%, setting a target price of HKD 16.6. Management stated that Sanbexin, Quviviq, and the new oncology drug combination continue to drive product sales growth, and a recent collaboration with Roche on preclinical TCE is expected to bring in an additional USD 75 million upfront payment.